Introduction
Tumor angiogenesis plays a key role in the development of a wide variety of malignant tumors. 1 Whereas smaller tumor cell conglomerates can sufficiently be nourished by diffusion, further tumor growth of nodules with more than 1-2 mm 3 in volume depends on tumor angiogenesis. Increasing tumor size requires adequate nutrition, oxygenation and metabolization by improved blood supply that can be achieved by sprouting of new vessel branches from pre-existing ones. This finding forms the rationale behind angiostatic anti-cancer therapies that are aimed at pushing the equilibrium between pro-and antiangiogenic factors in favor of antiangiogenic factors. Antiangiogenic anti-cancer approaches block tumor vascularization or tumor angiogenesis by attacking pre-existing vessels or inhibiting the sprouting of new branches from those vessels.
AdmuthPlgK3 and AdK1-3 in mice results in significantly decreased endothelial cell infiltration in VEGF-embedded Matrigel plugs. Treatment with AdmuthPlgK3 and AdK1-3 exerts strong antitumoral effect in models of hepatocellular carcinoma and Lewis lung cancer. This antitumor effect was associated with decreased microvessel density in the tumors. Taken together, our data demonstrate that angiostatin endowed with strong antiangiogenic and antitumor effects can be released from a furin-mutated plasminogen acting as a precursor. This strategy may have potential to develop angiostatic anti-cancer therapies.
Gene Therapy (2002) 9, 1600-1606. doi:10.1038/sj.gt.3301805 a process that can restrain metastasis. 6, 7 Angiostatin can inhibit bFGF-induced endothelial cell proliferation in vitro and bFGF-induced angiogenesis in vivo. 5 It has been demonstrated that other fragments of plasminogen, such as the first three kringle (K1-3) domains and kringle 5 (K5) exhibit potent inhibitory activities on endothelial cell proliferation. 8, 9 Inhibition of angiogenesis by treatment with angiostatin causes significant suppression of tumor growth in both murine and human tumor models. 5, [10] [11] [12] Gene therapy strategies against cancer by transfer of a DNA sequence encoding the region of plasminogen corresponding to angiostatin have been applied in different tumor models. [13] [14] [15] [16] The ubiquitous endoprotease furin is involved in the physiologic conversion of a broad spectrum of precursors into active protein compounds including several growth factors, hormones, plasma proteins, receptors, and matrix metalloproteinases. 17, 18 Furthermore some constituents of pathogens, such as human immunodeficiency virus gp160 and diphtheria toxin, are processed in this manner. 18 It has been known that the endoprotease furin recognizes a consensus cleavage site of -ArgXLys/ ArgArg. 17 The incorporation into pro-insulin of a furin cleavage site has been shown to result in the release of active insulin by stably transfected cells. In that study pro-protein to protein conversion reached 90% of the total amount of expressed pro-protein. 19 Also, retroviral gene transfer of rat preproinsulin-1 carrying a furin cleavage site leads to the secretion of active insulin capable of preventing ketoacidosis effectively. 20 Recently, furin cleavage site was used as a linker sequence to express multiple gene products from a single cistron comprising several proteins as one single fusion protein from which equimolar amounts of different active products were liberated by furin cleavage. 21 The objective of this study was to generate angiostatic kringles of plasminogen by processing this molecule through the physiological intracellular pathway for constitutive protein secretion. To this aim we incorporated the sequences of furin cleavage sites into human plasminogen cDNA between kringle region (K) three (K3) and four (K4). We have used an adenoviral vector to transfer furin-mutated plasminogen cDNA (AdmuthPlgK3) and to study the antiangiogenic and antitumor effects of the substance thus generated. Our data show that cells transduced with AdmuthPlgK3 release the first three kringle regions of plasminogen (K1-3) and this vector causes potent antiangiogenic and antitumor effects.
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Results
Construction of adenoviruses containing mutated furinsensitive plasminogen (AdmuthPlgK3) and first three kringles of plasminogen (AdK1-3)
We constructed mutated plasminogen carrying a furin restriction site between K3 and K4 by site-directed mutagenesis. The ProValSerThr amino acid sequence between K3 and K4 at position 1069-1072 of wild-type human plasminogen cDNA was changed to four arginines. The mutated furin-sensitive sequence was confirmed by sequencing as shown in Figure 1a . Recombinant adenoviruses, AdmuthPlgK3 carrying mutated furin-sensitive plasminogen and AdK1-3 carrying the first three kringles of plasminogen, were generated. In order to know whether the mutated plasminogen could be cleaved by furin, the conditioned medium (CM) from A549 cells infected in vitro with either AdmuthPlgK3, AdK1-3 or control vector AdlacZ was analyzed by Western blot using a polyclonal antibody against human plasminogen. As shown in Figure 1b , in CM from AdK1-3 infected cells three bands were observed in the MW range of 38 kDa corresponding to different postranscriptional glycosylation forms of the K1-3 fragment. 7 The same bands were also detected in the CM from AdmuthPlgK3-infected cells. In the CM from these cells, two other bands were observed corresponding to sizes of plasminogen (98 kDa) and of the predicted furin cleavage product (C-terminal) of the mutated plasminogen (60 kDa). These data indicate that the mutated plasminogen can be cleaved to yield an angiostatin-like molecule that is secreted to the culture medium of the adenovirusinfected cells.
Biological activity of angiostatin like molecules produced by AdmuthPlgK3 and AdK1-3 in vitro
To evaluate the anti-proliferative effect of CM from A549 cells infected with AdmuthPlgK3, AdK1-3 or control vector AdlacZ, HUVE cells were pre-incubated with CM at final concentration of 30%. We found that pre-incubation of HUVE cells with CM from AdK1-3 and AdmuthPlgK3-infected cells inhibited proliferation by 39% and 29%, respectively, as compared with CM from uninfected cells. This inhibitory effect appeared to be dose-dependent, since inhibition was less pronounced in assays with CM at final concentration of 15% (data not shown). CM from AdlacZ-infected cells had no inhibitory effect on proliferation of HUVE cells (data not shown). The effect on migration of HUVE cells exerted by CM from AdK1-3-, AdmuthPlgK3-or AdlacZ-infected A549 cells was quantified in a modified double chamber migration assay. We found that the percentage of cell migration was reduced by 64% and 78%, as compared with the control group when using CM from AdK1-3 and AdmuthPlgK3, respectively ( Figure 2a from AdlacZ-infected cells had no inhibitory effect on tube formation (Figure 2 ). Taken together, these in vitro data demonstrate that angiostatin produced from either AdmuthPlgK3 or AdK1-3 exerts biological activities on endothelial cells.
b-f) Inhibition of HUVE cell tube formation by angiostatin expressed by adenoviral vectors. HUVE cells were pre-incubated with CM for 30 min in Matrigel-coated culture wells and were cultured in culture medium supplemented with growth factor for an additional 6 h. At this time-point, HUVE cells started to form capillary-like structures (b). Addition of CM from AdlacZ-infected cells did not affect tube formation (c). In contrast, addition of CM from AdK1-3 and AdmuthplgK3 infected cells inhibited tube formation (d, e). (f). Intact tubes were quantified in the whole
Inhibition of angiogenesis in vivo by systemic administration of AdmuthPlgK3 and AdK1-3
We have also explored whether angiogenesis could be inhibited in vivo after systemic administration of the adenoviral vectors AdmuthPlgK3 and AdK1-3. To this aim, animals were inoculated s.c. with VEGF-containing Matrigel 6 h after systemic administration of AdmuthPlgK3, and AdK1-3 or control vector AdlacZ. Fourteen days later, mice were killed and Matrigel plugs were collected for histological examination. As shown in Figure 3a and b, an intense invasion by endothelium-like cells was observed in Matrigel plugs from animals receiving saline and control vector AdlacZ. In contrast, Matrigel plugs from mice which received AdK1-3 or AdmuthPlgK3 had much less infiltration of endotheliumlike cells (Figure 3c and d) . Quantitative estimation of endothelium-like cells on Matrigel sections (Figure 3e ) showed that administration of AdK1-3 and AdmuthPlgK3 resulted in a reduction of cell infiltration of 51% and 43%, respectively, in comparison to animals receiving the control vector AdlacZ. 
Effect of systemic administration of AdK1-3 and AdmuthPlgK3 on the inhibition of tumor growth in athymic mice bearing HCC tumors
The antitumoral potency of AdK1-3 and AdmuthPlgK3 was firstly evaluated in subcutaneous HCC tumors in athymic mice. Ten days after tumor cell inoculation, mice were treated by intravenous injection of AdK1-3 or AdmuthPlgK3 or AdlacZ at the dose of 1 × 10 10 p.f.u./animal or saline. As shown in Figure 4 , treatment with AdK1-3 or AdmuthPlgK3 caused a significant inhibition of tumor growth, as compared with animals treated with control vector AdlacZ or saline.
Inhibition of tumor growth on established LLC tumor in C57BL/6 and athymic mice by systemic administration of AdK1-3 and AdmuthPlgK3
We have also analyzed the antitumoral effect of AdK1-3 and AdmuthPlgK3 on well-established subcutaneous LLC tumors in syngenic C57BL/6 mice and athymic mice. When tumor size was about 50 mm 3 in volume in both models, animals were treated by intravenous administration of AdK1-3 or AdmuthPlgK3 or AdlacZ at a dose of 1 × 10 10 p.f.u./animal. Figure 5 showed that treatment with AdK1-3 or AdmuthPlgK3 caused a significant inhibition of tumor growth in both tumor-bearing C57BL/6 mice and athymic mice. Administration of control vector AdlacZ had no effect on tumor growth ( Figure 5 ). In tumor-bearing C57BL/6 mice we observed, at day 2 and 4 after treatment, a reduction in tumor volume of 55% and 65% in AdK1-3-and AdmuthPlgK3-treated animals as compared with control animals receiving control vector AdlacZ (Figure 5a ). In athymic mice, at day 2 after therapy, the reduction in tumor volume was 53% and 37% as compared with control animals, in AdK1-3-and AdmuthPlgK3-treated mice, respectively (Figure 5b) .
Effect of AdmuthPlgK3 and AdK1-3 on tumor angiogenesis
Microvessel density in the tumors was determined by immunohistochemistry for von Willebrand factor, as a marker for endothelial cells. Athymic mice with subcutaneous LLC tumor of about 50 mm 3 in volume were treated by intravenous administration of AdK1-3 or the AdmuthPlgK3 at dose of 1 × 10 10 p.f.u./animal or control vector AdlacZ at the same dose or saline. Tumors were removed 7 days after treatment. As shown in Figure 6a and b, tumors from animals receiving saline or control vector AdlacZ, showed intensive staining for von Willebrand factor, indicating the presence of extensive angiogenesis in this type of tumor. Tumors from AdK1-3 or AdmuthPlgK3 treated animals showed a marked reduction of microvessel density (Figure 6c and d) . Quantitative analysis demonstrated 59% and 61% reduction of the intratumoral microvessel density in AdK1-3-and AdmuthPlgK3-treated animals, respectively, as compared with control animals receiving saline. Treatment Gene Therapy with control vector AdlacZ did not change intratumoral microvessel density (Figure 6b and e) .
Discussion
Here we show the production of a potent antiangiogenic factor from an engineered precursor molecule. The method described here is based on the incorporation of an endoproteolytic furin restriction site in between kringle region three (K3) and four (K4) of wild-type plasminogen cDNA. When this engineered molecule is expressed in eukaryotic cells, it becomes a precursor molecule allowing conversion into the active angiostatic K1-3 plasminogen fragment by ubiquitous endoprotease furin cleavage. The selection of a ubiquitous endoprotease furin for conversion of an engineered precursor would allow protein processing in practically all tissues. 17, 18 This is considered to be particularly attractive for angiostatic anti-cancer strategies, because the anti-angiogenic substance would be produced systemically thus obviating the need for transducing the tumoral tissue directly. 2, 3 In fact, high systemic levels of the antiangiogenic factor are desirable since no relevant side-effects have been described for plasminogen-derived angiostatic proteins, so far.
In this study we have used a first generation adenoviral vector as a vehicle to transfer mutant plasminogen in vitro and in vivo. A positive control adenovirus encoding only angiostatin K1-3 and a negative control vector AdlacZ were also used. Western blot analysis of conditioned culture medium of cells infected with the vector, AdmuthPlgK3, demonstrated that plasminogen was cut into the predicted, correct size cleavage products liberating kringle fragments K1-3 together with the remaining C-terminal fragment of plasminogen. Cleavage efficacy did not reach 100% as seen in the Western blot analysis because part of the secreted plasminogen remained uncleaved, an observation which is consistent with data from studies which exploited furin sites as linker sequences to produce multiple gene products from mono-cistronic expression of one fusion gene. Cleavage efficacy was described to range between 50% and 90% of total amount of secreted protein. 19, 21, 22 As incomplete precursor cleavage might interfere with functional activity, we studied different functional effects of AdmuthPlgK3 on endothelial cell function in comparison to AdK1-3 and the control vector AdlacZ. Our data showed that both vectors had effect on the inhibition of proliferation, migration and tube formation of endothelial cells. This also holds true for in vivo antiangiogenic effects since both constructs, AdK1-3 and AdmuthPlgK3, had antiangiogenic potency in an in vivo Matrigel angiogenesis assay, when the vectors were administered systemically. These data indicate that mutant plasminogen can be cleaved into an angiostatin-like molecule that exerts antiangiogenic bioactivity in vitro and in vivo conditions.
Furthermore, we have demonstrated that both AdmuthPlgK3 and AdK1-3 showed strong antitumoral effect in a subcutaneous HCC model in a similar manner. We also studied the antitumoral efficacy of these constructs in established LLC in immune-competent C57BL/6 and in immune-deficient athymic mice. We found that both vectors could inhibit tumor growth either in C57BL/6 or athymic mouse models. This antitumor effect was mediated by antiangiogenic mechanisms, since intratumoral microvessel density detected by immunohistochemistry is clearly decreased in animals receiving either AdK1-3 or AdmuthPlgK3. Although others and ourselves found that vector-mediated gene transfer of angiostatin could induce significant inhibition of tumor growth, this type of therapy was not sufficient to induce complete tumor regression, even in a prophylactic setting. [13] [14] [15] [16] 23 Recent reports have demonstrated that combination of anti-angiogenic therapy (angiostatin and vasostatin) and immunotherapy (interleukin-12) had synergistic effect on tumor regression in different mouse tumor models. 24, 25 This synergism can be explained by the fact that the antiangiogenic therapy induces tumor cell death and releases tumor antigens which potentiate the immune response elicited by immunotherapy. Another possible explanation could be that the host's immune system might get easier access to tumor cells when angiostatic compounds compromise the tumor vasculature.
The attractiveness of our strategy for the generation of angiostatic molecules is based on the fact that by using this approach it would be feasible to generate several angiostatic active kringle regions from multiple mutated plasminogen sequences. By this means synergistic and/or additive antiangiogenic effects of the plasminogen kringle derivates can be exploited by the enzymatic release of multiple compounds from a single precursor construct.
In summary, this study demonstrates that active antiangiogenic kringle regions of plasminogen can be released from full length furin-mutated plasminogen (muthPlgK3) by enzymatic cleavage and that adenovirusmediated gene transfer of this construct exerts a strong antiangiogenic and antitumor effect.
Materials and methods
Animals and cell lines C57BL/6 or athymic mice, 5 to 8 weeks old, were purchased from Harlan (Barcelona, Spain). During the experimental period, C57BL/6 mice were housed in standard conditions and athymic mice received special care and were kept in pathogen-free single ventilated cages. All animal procedures were performed according to approved protocols and in accordance with recommendations for proper care and use of laboratory animals.
The human and the murine lung cancer cell lines A549 and LLC cells, and 293 cell line (embryonic E1 transformed kidney cell line) were obtained from American Type Culture Collection (ATCC, Rockville, MD, USA). Cells were cultured in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS). HUVE (human umbilical vein endothelial) cells were obtained from Cascade Biologics (Portland, OR, USA) and were cultured according to the supplier's instructions. Human hepatocellular carcinoma cell line Huh-7 was cultured in DMEM supplemented with 10% FBS.
Construction of recombinant adenoviruses encoding furin-mutated plasminogen and angiostatin K1-3
The human plasminogen cDNA (kindly donated by Professor DeFord, University of NotreDame) was used for site-directed mutagenesis according to the manufacturer's protocol (GeneEditor in vitro Site-Directed Mutagenesis System; Promega, Madison, WI, USA). The mutation oligo 5'-GTTTTATTTGAAAGGCGCCGGC GTCTCTCAGAGTGC-3' was used to introduce a furin restriction site in between K3 and K4 of plasminogen, replacing residues 1069-1072 coding for ProValSerThr by ArgArgArgArg. The resulting gene fragment muthPlgK3 was cloned into adenoviral shuttle vector pMV60 with CMV immediate-early promoter upstream and polyA sequence downstream of the insertion site. 26 The angiostatin K1-3 was generated by PCR technique using human plasminogen cDNA plasmid as template with primers 5'-GCGGCCGCATGGAACATAAGGAAGTGGTTC-3' and 5'-GCGGCCGCTTAGGAGTCACAGGACGGTATCT-3' and cloned into pCR2.1-TOPO (Invitrogen, Carlsbad, CA, USA). The sequence was confirmed by DNA sequencing. The angiostatin K1-3 sequence was cloned into pMV60. Recombinant adenoviruses were constructed as described previously. 26 
Western blot
Ten l of conditioned culture medium (CM) of A549 cells which were infected with AdmuthPlgK3, AdK1-3 or AdlacZ for 70 h was used for electrophoresis in 10% SDS-PAGE. Membranes were hybridized with a polyclonal antibody against plasminogen (Biogenesis, Pools, UK) and a secondary antibody against rabbit IgG (Sigma, St Louis, MO, USA) and were developed according to the protocol (ECL-Plus, Amersham Pharmacia Biotech, Little Chalfont, UK).
Migration assay
Inserts (8 m pores, Costar) for 24-well culture plates were coated with 100 g/ml of rat tail collagen type I (Becton Dickinson, Bedford, MA, USA). HUVE cells with passage number of 4-6 were resuspended in Medium 200 containing 1% BSA (Sigma) at a concentration of 25 000 cells/50 l. Fifty l of cell resuspension were seeded into the upper chamber. The lower chamber was filled with Medium 200 containing 1% BSA. HUVE cells were preincubated with 50 l of CM at 37°C for 30 min before adding vascular endothelial growth factor (VEGF) at a final concentration of 5 ng/ml to the lower chamber. These chambers were incubated for 6 h to allow cells to migrate through the collagen-coated pore membranes. The non-migrated cells were thoroughly scraped off the upper surface membrane with cotton swabs. The mem-brane was stained with Diff-Quick (DADE BEHRING, Dü dingen, Switzerland). Five to eight representative fields in each well were counted at 100× magnification to determine the number of migrated cells. The migration was expressed as percentage of maximal migration (defined as migration with VEGF stimulation without addition of CM).
Tube formation assay
The 24-well plates were coated with 320 l Matrigel. HUVE cells (25 000 cells/75 l) were dispensed into each well and were incubated with 75 l of CM for 30 min. After adding 150 l Medium 200 containing 10% low serum growth supplement (LSGS; Cascade Biologics, Portland, OR, USA), cells were incubated for another 6 h. Tube formation was quantified by counting intact tubes in the whole well under microscopy at 40× magnification.
In vivo testing of antiangiogenic effects (Matrigel angiogenesis assay)
The Matrigel assay was performed with modifications as described previously. 27 Athymic mice were treated by intravenous injection of AdmuthPlgK3, AdK1-3 or AdlacZ at dose of 10 10 p.f.u. per animal. Six h later 150 l of VEGF-embedded Matrigel was injected subcutaneously into the left and right mid-abdominal region of mice. After 14 days, mice were killed and Matrigel plugs were removed and sections were stained by HE. Quantitative analysis was done by counting the total number of endothelial-like cells in the Matrigel plugs with Indexed Squared Micrometer, 21mm (ProSciTech, Thuringowa Old, Australia) under microscope. Results were expressed as the mean (± s.e.m.) cell number per square scale (mm 2 ).
In vivo testing of antitumoral effects
In the tumor model of hepatocellular carcinoma (HCC) in athymic mice, 2 × 10 6 of Huh-7 were implanted subcutaneously into the right hind flank of athymic mice. After 10 days, mice were treated by intravenous injection of AdmuthPlgK3, AdK1-3 or AdlacZ at dose of 10 10 p.f.u. per animal. In models of Lewis lung carcinoma (LLC) in C57BL/6 and athymic mice, 10 6 LLC cells were injected subcutaneously in the right hind flank of mice. When tumor reached 50 mm 3 in volume, animals were treated by intravenous injection of AdmuthPlgK3, AdK1-3 or AdlacZ at dose of 10 10 p.f.u. per animal. Tumor growth was monitored every day for the first week after treatment and every 2 days in the second week by measuring tumor size using calipers. The tumor volume was calculated by the formula: V = length × width 2 × 0.52.
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Assessment of microvessel density The paraffin sections of tumors which received therapy with adenoviral vectors were treated with proteinase K (DAKO, Glostrup, Denmark) for 10 min at room temperature and endogenous peroxidase activity was quenched by H 2 O 2 -treatment (DAKO) for 5 min. Sections were then blocked with 5% goat serum in Tris buffer containing 0.1% Tween 20, followed by incubation with rabbit antivon Willebrand factor (factor VIII-related antigen, DAKO) for 20 min at room temperature. Antibody binding was detected by sequential incubation of the sections with LSAB2 system (DAKO). Enzymatic activity was developed using DAB (DAKO) as chromogenic substrate. After counterstaining with Mayer hematoxylin, samples were mounted and examined by light microscopy. The microvessel density was assessed according to the method described by Weidner et al. 29 Areas presenting highest vascularization were identified and microvessels counted in high power fields (×400 magnification). For each section 10 fields were evaluated.
